Jacobson Pharma Corporation Limited, through its subsidiaries, manufactures, markets, and sells generic drugs and branded healthcare products in Hong Kong, China, Macau, Singapore, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$0.60|
|52 Week High||HK$0.58|
|52 Week Low||HK$1.40|
|1 Month Change||-10.45%|
|3 Month Change||-14.29%|
|1 Year Change||-49.15%|
|3 Year Change||-62.50%|
|5 Year Change||-59.73%|
|Change since IPO||-64.29%|
Recent News & Updates
Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015
Jacobson Pharma Corporation Limited ( HKG:2633 ) has announced it will be reducing its dividend payable on the 19th of...
Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year
Shareholders will probably not be too impressed with the underwhelming results at Jacobson Pharma Corporation Limited...
Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares
Whilst it may not be a huge deal, we thought it was good to see that the Jacobson Pharma Corporation Limited ( HKG:2633...
|2633||HK Pharmaceuticals||HK Market|
Return vs Industry: 2633 underperformed the Hong Kong Pharmaceuticals industry which returned -16% over the past year.
Return vs Market: 2633 underperformed the Hong Kong Market which returned 5% over the past year.
Stable Share Price: 2633 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 2633's weekly volatility (7%) has been stable over the past year.
About the Company
Jacobson Pharma Corporation Limited, through its subsidiaries, manufactures, markets, and sells generic drugs and branded healthcare products in Hong Kong, China, Macau, Singapore, and internationally. The company offers generic drugs for various therapeutic categories, including respiratory, cardiovascular, central nervous system, gastrointestinal, scar treatment, oral anti-diabetics, anti-infective, arsenic trioxide oral solution, dihydrocodeine tablet, perindopril tablet, atomoxetine capsule, rosuvastatin tablet, hydroxychloroquine tablet, desloratadine tablet, metronidazole gel, and ofloxacin eye drops. It also provides branded medicines; health and wellness products; and proprietary Chinese medicines, such as Po Chai pills, Ho Chai Kung Tji Thung San, Tong Tai Chung Woodlok oil, Flying Eagle Woodlok Oil, Saplingtan, Shiling oil, Contractubex, Doan's Ointment, and Col-gan tablet.
Jacobson Pharma Fundamentals Summary
|2633 fundamental statistics|
Is 2633 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|2633 income statement (TTM)|
|Cost of Revenue||HK$884.83m|
Last Reported Earnings
Mar 31, 2021
Next Earnings Date
|Earnings per share (EPS)||0.091|
|Net Profit Margin||12.01%|
How did 2633 perform over the long term?See historical performance and comparison
3.8%Current Dividend Yield
Is Jacobson Pharma undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 2633 (HK$0.6) is trading below our estimate of fair value (HK$3.25)
Significantly Below Fair Value: 2633 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 2633 is good value based on its PE Ratio (6.6x) compared to the Hong Kong Pharmaceuticals industry average (9.9x).
PE vs Market: 2633 is good value based on its PE Ratio (6.6x) compared to the Hong Kong market (9.6x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2633's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 2633 is good value based on its PB Ratio (0.5x) compared to the HK Pharmaceuticals industry average (1x).
How is Jacobson Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Jacobson Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Jacobson Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2633 has a large one-off gain of HK$91.4M impacting its March 31 2021 financial results.
Growing Profit Margin: 2633's current net profit margins (12%) are lower than last year (13.6%).
Past Earnings Growth Analysis
Earnings Trend: 2633's earnings have grown by 6.1% per year over the past 5 years.
Accelerating Growth: 2633's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 2633 had negative earnings growth (-18.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (23.8%).
Return on Equity
High ROE: 2633's Return on Equity (6.5%) is considered low.
How is Jacobson Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: 2633's short term assets (HK$1.2B) exceed its short term liabilities (HK$873.9M).
Long Term Liabilities: 2633's short term assets (HK$1.2B) exceed its long term liabilities (HK$1.1B).
Debt to Equity History and Analysis
Debt Level: 2633's debt to equity ratio (55.2%) is considered high.
Reducing Debt: 2633's debt to equity ratio has increased from 49.5% to 55.2% over the past 5 years.
Debt Coverage: 2633's debt is well covered by operating cash flow (25.9%).
Interest Coverage: 2633's interest payments on its debt are well covered by EBIT (5.9x coverage).
What is Jacobson Pharma current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 2633's dividend (3.83%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.29%).
High Dividend: 2633's dividend (3.83%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.81%).
Stability and Growth of Payments
Stable Dividend: 2633 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 2633's dividend payments have increased, but the company has only paid a dividend for 5 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (25.4%), 2633's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Derek Sum (58 yo)
Mr. Kwong Yip Sum, also known as Derek, is Non-Executive Chairman of the Board at JBM (Healthcare) Limited since September 22, 2020. He joined the company and its subsidiaries September 22, 2020. With exte...
CEO Compensation Analysis
Compensation vs Market: Derek's total compensation ($USD637.93K) is above average for companies of similar size in the Hong Kong market ($USD230.70K).
Compensation vs Earnings: Derek's compensation has been consistent with company performance over the past year.
Experienced Board: 2633's board of directors are considered experienced (5.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Jacobson Pharma Corporation Limited's employee growth, exchange listings and data sources
- Name: Jacobson Pharma Corporation Limited
- Ticker: 2633
- Exchange: SEHK
- Founded: 2016
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$1.149b
- Shares outstanding: 1.92b
- Website: https://www.jacobsonpharma.com
Number of Employees
- Jacobson Pharma Corporation Limited
- Tower 1, Millennium City
- 23rd Floor
- Kwun Tong
- Hong Kong
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/15 15:52|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.